155 related articles for article (PubMed ID: 2516494)
1. Treatment of chronic myelogenous leukemia with interferons: hematologic, cellular, and genetic investigations.
Opalka B; Kloke O; Wandl U; Becher R; Niederle N
Haematol Blood Transfus; 1989; 32():134-8. PubMed ID: 2516494
[No Abstract] [Full Text] [Related]
2. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.
Opalka B; Wandl UB; Becher R; Kloke O; Nagel-Hiemke M; Moritz T; Beer U; Seeber S; Niederle N
Blood; 1991 Nov; 78(9):2188-93. PubMed ID: 1932740
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center.
Kantarjian HM; Talpaz M
Leuk Lymphoma; 1993; 11 Suppl 1():169-74. PubMed ID: 8251891
[No Abstract] [Full Text] [Related]
4. CML: new biologic therapies, endpoints and questions.
Martin A; Cheson BD
Oncology (Williston Park); 1987 Sep; 1(7):12-3, 16. PubMed ID: 3152809
[No Abstract] [Full Text] [Related]
5. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.
Talpaz M; Kurzrock R; Kantarjian H; Rothberg J; Saks S; Evans L; Gutterman JU
Cancer; 1991 Nov; 68(10):2125-30. PubMed ID: 1913450
[TBL] [Abstract][Full Text] [Related]
6. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
Guilhot F; Dreyfus B; Desmarest MC; Giraud C; Huret JL; Brizard A; Tanzer J
Nouv Rev Fr Hematol (1978); 1989; 31(2):171-3. PubMed ID: 2771633
[TBL] [Abstract][Full Text] [Related]
7. Interferon alfa-2c in chronic myelogenous leukemia (CML): hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon gamma.
Herrmann F; Jonas D; Helfrich SG; Lindemann A; Schleiermacher E; Mertelsmann R
Blut; 1990 Oct; 61(4):226-31. PubMed ID: 2121299
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.
Talpaz M; Kantarjian H; Kurzrock R; Trujillo JM; Gutterman JU
Ann Intern Med; 1991 Apr; 114(7):532-8. PubMed ID: 2001086
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic prospects of interferon in patients with chronic myelocytic leukemia].
Podsiadło Z; Skotnicki AB; Blicharski J
Przegl Lek; 1988; 45(9):687-9. PubMed ID: 3075051
[No Abstract] [Full Text] [Related]
10. Prolonged hematological remission by mitoxantrone and interferon--alpha-2b in a child with resistant Philadelphia chromosome-positive chronic myelogenous leukemia.
Duru F; Tuncer M; Hiçsönmez G
Eur J Haematol; 1993 Sep; 51(3):173-4. PubMed ID: 8405332
[No Abstract] [Full Text] [Related]
11. Complete cytogenetic and molecular remission in a case of lymphoid blast crisis in chronic myeloid leukemia with intensive chemotherapy and interferon alpha.
Fabbiano F; Santoro A; Di Trapani F; Marino MA; Pampinella M; Caronia F
Eur J Haematol; 1993 Aug; 51(2):122-3. PubMed ID: 8370420
[No Abstract] [Full Text] [Related]
12. A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia.
Kloke O; Wandl U; Opalka B; Moritz T; Nagel-Hiemke M; Franz T; Becher R; Hirche H; Seeber S; Niederle N
Eur J Haematol; 1992 Feb; 48(2):93-8. PubMed ID: 1547881
[TBL] [Abstract][Full Text] [Related]
13. [Chronic myeloid leukemia].
Hochhaus A
Dtsch Med Wochenschr; 2011 Oct; 136(40):2007-10. PubMed ID: 21960328
[No Abstract] [Full Text] [Related]
14. [The treatment of chronic myeloid leukemia in chronic phase with interferons].
Guilhot F
Pathol Biol (Paris); 1988 Dec; 36(10):1179-81. PubMed ID: 3070457
[No Abstract] [Full Text] [Related]
15. Interferon alfa as primary treatment of chronic myeloid leukemia: long-term follow-up of 71 patients observed in a single center.
Kloke O; Opalka B; Niederle N
Leukemia; 2000 Mar; 14(3):389-92. PubMed ID: 10720131
[TBL] [Abstract][Full Text] [Related]
16. How cells respond to interferons.
Pitini V; Arrigo C; Altavilla G
J Clin Oncol; 2010 Sep; 28(25):e439; author reply e440. PubMed ID: 20644099
[No Abstract] [Full Text] [Related]
17. Therapy of chronic myelogenous leukemia.
Talpaz M; Kantarjian H; McCredie K; Trujillo J; Keating M; Gutterman JU
Cancer; 1987 Feb; 59(3 Suppl):664-7. PubMed ID: 10822467
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon.
Lee JT; Park S; Lee JH; Kim BK; Kim NK
J Korean Med Sci; 1996 Feb; 11(1):26-32. PubMed ID: 8703367
[TBL] [Abstract][Full Text] [Related]
19. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.
Freund M; von Wussow P; Knüver-Hopf J; Mohr H; Pohl U; Exeriede G; Link H; Wilke HJ; Poliwoda H
Blut; 1988 Nov; 57(5):311-5. PubMed ID: 3196882
[TBL] [Abstract][Full Text] [Related]
20. Interferon alpha in the therapy of CML.
Talpaz M; Kantarjian H; Kurzrock R; Gutterman JU
Br J Haematol; 1991 Oct; 79 Suppl 1():38-41. PubMed ID: 1931707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
